162439-39-6

Basic information

• Product Name: (4S)-4-benzyl-3-<(2'R)-2'-<(tert-butoxycarbonyl)methyl>-6'-(phenylmethoxy)hexanoyl>-2-oxazolidone
• Synonyms: (4S)-4-benzyl-3-<(2'R)-2'-<(tert-butoxycarbonyl)methyl>-6'-(phenylmethoxy)hexanoyl>-2-oxazolidone
• CAS NO: 162439-39-6
• Molecular Weight: 495.616
• Mol File: 162439-39-6.mol

Chemical Properties

• CAS DataBase Reference: (4S)-4-benzyl-3-<(2'R)-2'-<(tert-butoxycarbonyl)methyl>-6'-(phenylmethoxy)hexanoyl>-2-oxazolidone(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-benzyl-3-<(2'R)-2'-<(tert-butoxycarbonyl)methyl>-6'-(phenylmethoxy)hexanoyl>-2-oxazolidone(162439-39-6)
• EPA Substance Registry System: (4S)-4-benzyl-3-<(2'R)-2'-<(tert-butoxycarbonyl)methyl>-6'-(phenylmethoxy)hexanoyl>-2-oxazolidone(162439-39-6)

Safety Data

• Hazardous Substances Data: 162439-39-6(Hazardous Substances Data)

Upstream product

• 162439-38-5 6-benzyloxyhexanoic acid chloride 
• 130892-97-6 6-benzyloxyhexanoic acid 
• 100-39-0 benzyl bromide 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 629-11-8 1,6-hexanediol 

Downstream Products

• 1026468-03-0 (R)-7-(4-Chloro-phenoxy)-3-{(S)-2,2-dimethyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-propylcarbamoyl}-heptanoic acid 
• 1027285-93-3 (R)-7-(4-Chloro-phenoxy)-3-{(S)-2,2-dimethyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-propylcarbamoyl}-heptanoic acid tert-butyl ester 
• 1027541-54-3 (R)-7-(4-Chloro-phenoxy)-3-[(S)-2,2-dimethyl-1-(2-pyridin-2-yl-ethylcarbamoyl)-propylcarbamoyl]-heptanoic acid tert-butyl ester 
• 1026501-64-3 (R)-7-(4-Chloro-phenoxy)-3-((S)-2,2-dimethyl-1-phenethylcarbamoyl-propylcarbamoyl)-heptanoic acid tert-butyl ester 
• 1025991-21-2 (R)-7-(4-Chloro-phenoxy)-3-[(S)-2,2-dimethyl-1-(3-morpholin-4-yl-propylcarbamoyl)-propylcarbamoyl]-heptanoic acid tert-butyl ester 
• 169270-10-4 (R)-3-((S)-1-Methylcarbamoyl-2-phenyl-ethylcarbamoyl)-6-phenethylcarbamoyl-hexanoic acid tert-butyl ester 

Relevant articles and documents

Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group

In this study, structure-based drug design of matrix metalloproteinase inhibitors [human fibroblast collagenase (HFC), human fibroblast stromelysin (HFS), and human neutrophil collagenase (HNC)] was utilized in the development of potent hydroxamates which